Impaired renal magnesium reabsorption from low or depleted magnesium levels carries a notable association with worse kidney outcomes, shown by adjusted odds ratios of 1.7–3.0 in affected patients. This contributes to electrolyte imbalances and may worsen overall kidney function over time, with studies reporting hypomagnesemia in nearly a quarter of patients who already have impaired renal function. Monitoring renal function and magnesium status remains crucial for at-risk individuals to avert complications such as acute kidney injury or hospitalization. This medication is commonly used for Stomach Acid.
Ferrè S, Li X, Adams-Huet B, Maalouf NM, Sakhaee K, Toto RD, Moe OW, Neyra JA. Low serum magnesium is associated with faster decline in kidney function: the Dallas Heart Study experience. J Investig Med. 2019 Aug;67(6):987-994.Steven Van Laecke, Wim Van Biesen, Raymond Vanholder, Hypomagnesaemia, the kidney and the vessels, Nephrology Dialysis Transplantation, Volume 27, Issue 11, November 2012, Pages 4003–4010. Sarah Cascaes Alves, Cristiane Damiani Tomasi, Larissa Constantino, Vinícius Giombelli, Roberta Candal, Maria de Lourdes Bristot, Maria Fernanda Topanotti, Emmanuel A. Burdmann, Felipe Dal-Pizzol, Cassiana Mazon Fraga, Cristiane Ritter, Hypomagnesemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury, Nephrology Dialysis Transplantation, Volume 28, Issue 4, April 2013, Pages 910–916. Liu Z, Wang R, He M, Kang Y. Hypomagnesemia Is Associated with the Acute Kidney Injury in Traumatic Brain Injury Patients: A Pilot Study. Brain Sci. 2023 Mar 31;13(4):593.
Some side effects may be linked to nutrient depletion caused by this medication.
Studies find that proton pump inhibitors (PPIs) may increase your risk of magnesium deficiency. A large study involving over 100,000 participants found a significant association between PPI use and lower magnesium levels (hypomagnesemia). PPIs work by reducing stomach acid production, which can also play a role in magnesium absorption. Individuals taking PPIs, particularly long-term use, should consider magnesium supplementation to help protect against deficiency.
Long-term use of PPIs might raise the risk of calcium deficiency and weaken bones. A potential mechanism for this is chronic hypergastrinemia, a condition where the stomach produces excess gastrin due to PPI use. This can lead to parathyroid hyperplasia, where the parathyroid glands overproduce a hormone that pulls calcium from bones. Additionally, PPIs significantly reduce stomach acid production, which can hinder calcium absorption from food in the intestines. Individuals taking PPIs, especially individuals at higher risk of bone issues or those on long-term PPI therapy, should consider calcium supplementation to help protect against deficiency.
There is evidence that proton pump inhibitors (PPIs) might decrease vitamin C levels in the body. A study showed that even a short course of omeprazole, a common PPI, reduced vitamin C levels in healthy volunteers, regardless of their dietary intake. This suggests that PPIs may reduce the bioavailability of vitamin C, meaning the body has a harder time absorbing and using it. Vitamin C plays a crucial role in immune function and antioxidant defenses and therefore individuals using PPI therapy should consider supplementation with vitamin C to protect against a deficiency.